Education
About Us
Working with TipRanks
Follow Us
Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Top Page
Insight Molecular Diagnostics
(NASDAQ:IMDX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$7.00
▼(-3.18% Downside)
The score is held back primarily by weak financial performance—continued losses, negative operating cash flow, and balance-sheet risk—despite strong recent technical strength and a constructive earnings-call outlook driven by the upcoming FDA submission catalyst and disciplined cash management. Valuation remains constrained by lack of profitability and no dividend data.
Positive Factors
Product Development
The upcoming FDA submission for GraftAssure DX indicates significant progress in product development, potentially opening new revenue streams and enhancing market position in precision medicine.
Financial Stability
Strong cash reserves and no debt provide financial flexibility, allowing the company to invest in growth opportunities and manage operational expenses effectively.
Market Expansion
A large total addressable market offers significant growth potential, positioning the company to capture a substantial share in the expanding field of personalized medicine.
Negative Factors
Profitability Challenges
Ongoing negative profitability indicates challenges in cost management and revenue generation, which could hinder long-term financial health and investment capacity.
Balance Sheet Risk
High leverage and negative equity suggest financial instability, posing risks to solvency and limiting the company's ability to secure favorable financing terms.
Cash Flow Concerns
Negative cash flow metrics highlight liquidity issues, potentially restricting the company's ability to fund operations and invest in growth without external financing.
Insight Molecular Diagnostics (IMDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$203.80M
Dividend YieldN/A
Average Volume (3M)42.75K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth520.87%
EPS Growth36.11%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding28,664,436
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.53
Price to Sales (P/S)16.54
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue17.22
Enterprise Value/Gross Profit31.46
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$8.50Price Target Upside17.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Insight Molecular Diagnostics Business Overview & Revenue Model
Company DescriptionOncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
How the Company Makes MoneyIMDX generates revenue primarily through the sale of its molecular diagnostic tests and related services to healthcare providers and laboratories. Key revenue streams include direct sales of test kits, licensing agreements for its proprietary technology, and collaborations with pharmaceutical companies for companion diagnostics. Additionally, the company may benefit from strategic partnerships with healthcare organizations that facilitate access to a broader customer base. As the demand for personalized medicine continues to grow, IMDX's innovative testing solutions position it well within a lucrative market.
Insight Molecular Diagnostics Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 01, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a generally positive outlook with significant advancements in product development and financial stability. However, the uncertainty due to the government shutdown and slower-than-expected clinical trial enrollment presents challenges.Q3-2025 Updates
Positive Updates
Product Development and FDA Submission Progress
Insight Molecular Diagnostics is nearing FDA submission for GraftAssure DX, with plans to submit by the end of 2025. They have made significant progress in clinical trials and product development, including optimization of assay workflow and strong performance results from international studies.
Financial Stability and Cash Management
The company ended the quarter with $20 million in cash and no debt. They maintained a cash burn below their target, demonstrating effective cash management.
Clinical Trial and Registry Program Advancements
Successful implementation of a registry program to gather real-world data and clinician feedback, which is expected to aid in product adoption and market education.
Negative Updates
Government Shutdown Impact on FDA Submission
The FDA submission process is affected by the government shutdown, which has delayed responses to company queries, potentially impacting the timeline for regulatory approval.
Slow Clinical Trial Enrollment
The clinical trial enrollment is slower than desired, with some sites not contributing to the initial wave of data needed for FDA submission.
Company Guidance
In the recent call discussing Insight Molecular Diagnostics' third-quarter results for 2025, the company provided guidance on their strategic initiatives and financial outlook. The company is preparing for the FDA submission of their GraftAssure DX assay in December 2025, with anticipated FDA authorization in 2026. They are focused on expanding their market presence through a registry program and head-to-head comparisons with legacy technologies, aiming to enhance clinician engagement and utilization of their assay. Financially, the company ended the quarter with $20 million in cash and no debt, maintaining a cash burn rate below $6 million per quarter, with expectations for a slight increase in Q4 due to FDA submission and clinical trial expenses. Their total addressable market (TAM) is estimated to exceed $1 billion, driven by 150,000 transplanted organs annually across key markets, and the company is preparing to transition from a development stage to a commercial operation, emphasizing customer acquisition and market expansion.Insight Molecular Diagnostics Financial Statement Overview
Summary
Insight Molecular Diagnostics faces significant financial challenges. Despite some revenue growth and a strong gross profit margin, the company struggles with profitability, high leverage, and negative cash flows. These issues indicate potential financial instability and highlight the need for strategic financial restructuring and improved operational efficiency.Income Statement
Insight Molecular Diagnostics shows a mixed performance in its income statement. The company has achieved revenue growth, with a TTM revenue growth rate of 3.41%. However, profitability remains a significant concern, as evidenced by negative net profit margins (-14.90%) and EBIT margins (-14.87%). The gross profit margin is relatively healthy at 63.42%, indicating efficient cost management in production. Despite these strengths, the persistent negative net income highlights ongoing challenges in achieving profitability.Balance Sheet
The balance sheet of Insight Molecular Diagnostics reveals financial instability. The company has a high debt-to-equity ratio of 3.07, indicating significant leverage and potential financial risk. The negative stockholders' equity suggests potential solvency issues. Return on equity is also negative, reflecting the company's inability to generate profits from its equity base. These factors highlight the need for improved financial management and capital structure optimization.Cash Flow
The cash flow statement indicates challenges in cash generation. The company has a negative operating cash flow, and the free cash flow growth rate is declining at -6.29%. However, the free cash flow to net income ratio is slightly positive at 1.01, suggesting that the company is managing to convert some of its net income into free cash flow. Despite this, the overall negative cash flow metrics highlight liquidity concerns and the need for improved cash management.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.40M | 1.88M | 1.50M | 958.00K | 2.20M | 1.22M |
| Gross Profit | 2.41M | 740.00K | 413.00K | -18.00K | 1.42M | -639.00K |
| EBITDA | -58.47M | -59.02M | -23.12M | -13.31M | -48.46M | -30.54M |
| Net Income | -60.78M | -60.66M | -27.78M | -72.90M | -64.10M | -29.93M |
Balance Sheet | ||||||
| Total Assets | 43.94M | 35.08M | 74.89M | 100.09M | 159.56M | 55.42M |
| Cash, Cash Equivalents and Short-Term Investments | 18.69M | 8.64M | 9.43M | 20.43M | 33.85M | 7.82M |
| Total Debt | 3.13M | 3.66M | 2.87M | 3.54M | 5.68M | 8.63M |
| Total Liabilities | 53.13M | 47.35M | 54.42M | 60.50M | 94.35M | 21.94M |
| Stockholders Equity | -9.20M | -12.27M | 20.47M | 39.59M | 65.22M | 33.48M |
Cash Flow | ||||||
| Free Cash Flow | -23.91M | -21.23M | -23.61M | -49.91M | -38.19M | -27.21M |
| Operating Cash Flow | -21.99M | -20.71M | -23.32M | -45.57M | -35.94M | -25.98M |
| Investing Cash Flow | -1.92M | -512.00K | -932.00K | -4.34M | -13.96M | -11.75M |
| Financing Cash Flow | 39.16M | 20.43M | 12.19M | 35.81M | 78.36M | 22.80M |
Insight Molecular Diagnostics Technical Analysis
Positive
7.23
Price Trends
6.26
Positive
5.01
Positive
3.97
Positive
Market Momentum
0.47
Negative
61.68
Neutral
75.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMDX, the sentiment is Positive. The current price of 7.23 is above the 20-day moving average (MA) of 6.43, above the 50-day MA of 6.26, and above the 200-day MA of 3.97, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 75.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMDX.
Insight Molecular Diagnostics Risk Analysis
Insight Molecular Diagnostics disclosed 58 risk factors in its most recent earnings report. Insight Molecular Diagnostics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We currently market certain IVDs that have not been cleared by the FDA in reliance on the regulatory exemption for IVDs intended for RUO, but if the FDA determines that our RUO tests do not meet the applicable requirements for exemption or have intended uses that are inconsistent with RUO tests, we may be required to suspend commercialization of such products until we can obtain the requisite FDA clearance and/or subject to FDA warning or untitled letters, seizure, injunction, fines, or other enforcement action. Q3, 2024
Insight Molecular Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $203.80M | -2.55 | -9999.00% | ― | 520.87% | 36.11% | |
50 Neutral | $154.29M | -0.95 | ― | ― | -63.96% | -28.50% | |
48 Neutral | $113.23M | -1.45 | -81.13% | ― | -9.70% | 23.23% | |
48 Neutral | $29.40M | -0.95 | ― | ― | -14.92% | 72.81% | |
45 Neutral | $84.47M | -2.71 | -48.89% | ― | ― | -9.42% |
* Healthcare Sector Average
IMDX
Insight Molecular Diagnostics
7.23
5.08
236.28%
ATOS
Atossa Therapeutics
0.64
-0.24
-27.01%
MGNX
MacroGenics
1.75
-1.29
-42.43%
ELUT
Elutia
0.88
-2.05
-70.03%
SRZN
Surrozen
20.65
9.46
84.54%
TELO
Telomir Pharmaceuticals, Inc.
1.33
-3.25
-70.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.